By InnoCan Pharma on Thursday, 14 May 2020
Category: Pharmaceutical - BioTech

InnoCan Pharma prices previously announced C$10 million offering

viewInnoCan Pharma

The firm said it will use the cash to fund research and product development costs, sales, marketing and operating expenses

The offer is being led by Mackie Research Capital, as sole bookrunner, and Canaccord Genuity as co-lead agents, together with Haywood Securities Inc and PI Financial Corp

Corporation () has now priced its previously announced C$10 million offering at C$0.20 a unit.

As reported on May 12 this year, the company said it will use the cash to fund research and product development costs, sales, marketing and operating expenses. It will also be used for working capital and general corporate purposes.

READ: InnoCan Pharma Corp unveils plans to raise up to C$10 million 

Each unit consists of one company share and one share purchase warrant. Each warrant is exercisable into one company share at C$0.25 for 36 months following completion of the offer.

is a specialty pharma, which develops products that harness the properties of cannabinoids combined with smart delivery formulations.

The offer is being led by Mackie Research Capital, as sole bookrunner, and as co-lead agents, together with Haywood Securities Inc and PI Financial Corp.

InnoCan has also granted its agents an option to cover over-allotments and for market stabilization purposes, exercisable in whole or in part at any time up to 30 days from the closing, to increase the size of offering by up to 15% of the number of units sold.

The closing of the offering is currently expected to be on or about the week of May 28.

Contact the author at [email protected]

CSE:INNO

Market: CSE
Market Cap: $31.65 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Full interview: Innocan Pharma plans to collaborate with Tel Aviv University...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver to bring news the company has entered into a sponsored research agreement with Ramot at Tel Aviv University to collaborate with Tel Aviv University to develop a novel, revolutionary approach to treating...

3 weeks ago

2 min read

Related Posts